Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

3

By Patrick Wingrove Oct 29 (Reuters) – Eli Lilly raised its full-year revenue forecast and beat third-quarter earnings expectations on Thursday, propelled by surging demand for injectable weight-loss

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)